Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung […]

Read More »

Genentech’s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial

Genentech (RHHBY)’s investigational cancer drug atezolizumab successfully shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1, the company announced this morning. Atezolizumab, MPDL3280A, is an investigational monoclonal antibody designed to interfere with a protein called PD-L1 (Programmed Death Ligand-1). Atezolizumab is designed to target PD-L1 expressed […]

Read More »

Gilead Rumored to be Eying Achillion…Again

August 17, 2015By Mark Terry, Breaking News Staff At least one analyst is again speculating that Foster City, Calif.-based Gilead Sciences, Inc. (GILD) may be ready to acquire New Haven, Conn.-based Achillion Pharmaceuticals, Inc. (ACHN). Given the company’s strong financial performance this year, many analysts believe Gilead is in the market for a strategic […]

Read More »

Mylan, Perrigo Notch Wins in Their Takeover Fight

Rival generic-drug makers Mylan NV and Perrigo Co. both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April publicly bid for Perrigo, saying a combination would create a strong competitor in the quickly consolidating pharmaceuticals sector. Perrigo has rejected the price as too […]

Read More »

Women who work or lift a lot may struggle to get pregnant

Women who work more than 40 hours a week or routinely lift heavy loads may take longer to get pregnant than women who don’t, a U.S. study suggests. Researchers followed 1,739 nurses who were trying to get pregnant and estimated 16 percent of them failed to achieve this goal within 12 months, and 5 percent […]

Read More »

There’s little evidence to help avoid stress fractures

Although there are plenty of opinions about what causes tiny, painful stress fractures in the bones of regular runners, a new review of existing research finds solid evidence for only two risk factors. Having had a stress fracture in the past raised the risk of having them again by five-fold and being female more than […]

Read More »

Endo Announces U.S. District Court Ruling Upholding OPANA ER Intellectual Property

DUBLIN, Aug. 14, 2015 /PRNewswire/ — Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the Company’s opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term […]

Read More »

FDA Clears OxyContin for Some Pediatric Patients

The U.S. Food and Drug Administration said it has approved the use of the painkiller OxyContin in children as young as 11, for severe pain that can’t be adequately treated with other medications. An FDA spokesman said the agency granted the approval Thursday, after the drug’s manufacturer, Purdue Pharma LP, submitted clinical-trial data on the […]

Read More »

FDA approves use of opioid painkiller in 11-16 year olds

The U.S. Food and Drug Administration has approved the use of opioid painkiller OxyContin in patients aged 11 to 16 who have not benefited enough from alternatives. The long-acting drug already treats adults suffering from around-the-clock pain, and has been reformulated over the years to combat rising prescription drug abuse in the United States. ( […]

Read More »

Boston Scientific Cuts 455, Closes Two Facilities; Abbott Axes 244

Boston Scientific (NYSE:BSX) and Abbott (NYSE:ABT) are making cuts from their workforce, according to a California Warn notice report. Boston Scientific is slated to cut 455 employees as it closes 2 facilities in the Fremont and San Jose areas. The company said it is moving the operations to a manufacturing facility in Costa Rica. Help […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom